At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 24 enrolled
Drug / intervention
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin in Patients With Type 1 Diabetes, A Randomised, Quadruple Crossover Trial
In Brief
A Phase 3 clinical trial evaluating Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin for Diabetes Mellitus, Type 1. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesDenmark
CollaboratorsNovo Nordisk A/S
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartJun 2009
Primary CompletionJun 2010
TodayJul 2026
First PostedApr 28, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.2 years ago
Interventions
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulindrug
0.2 U/IU/kg subcutaneous injection, single dose